CRNX Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Conference Call & Webcast

Thursday, February 27 @ 4:30 p.m. ET

Domestic:         1-800-267-6316

International:    1-203-518-9783

Conference ID:  CRNXQ4

Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link () or by visiting the of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.

The webcast will be archived on the Investor Relations section of .

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, , is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:

Gayathri Diwakar

Head of Investor Relations



(858) 345-6340

Media:

Natalie Badillo

Head of Corporate Communications



(858) 345-6075



EN
06/02/2025

Underlying

CRNXCrinetics Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Crinetics Pharmaceuticals

 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fi...

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December       Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026       Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates               Management Hosting Conference Call at 4:30 p.m. ET Today         SAN DIEGO, Feb. 26, 2026 (GLOBE...

12h / 29m 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conf...

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern TimeWebcast link Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with i...

February 5, 2026 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 ...

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322    Webcast: Partici...

January 26, 2026 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in...

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAH SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congen...

January 22, 2026 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Und...

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,575 shares of its common stock and granted an aggregate of 25,525 restricted stock unit (“RSU”) awards to 10 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducemen...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch